Session

H. pylori (Posters)

THE LONG-TERM EFFECT OF THE ERADICATION OF HELICOBACTER PYLORI IN T2DM OR PREDM PATIENTS
THE LONG-TERM EFFECT OF THE ERADICATION OF HELICOBACTER PYLORI IN T2DM OR PREDM PATIENTS

ANTIBIOTIC RESISTANCE TRENDS OF HELICOBACTER PYLORI NAÏVE PATIENTS IN THE PERIOD 2013-2019: ANALYSIS OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
ANTIBIOTIC RESISTANCE TRENDS OF HELICOBACTER PYLORI NAÏVE PATIENTS IN THE PERIOD 2013-2019: ANALYSIS OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

REAL-WORLD COMPARATIVE EFFECTS OF THREE-IN-ONE SINGLE CAPSULE BISMUTH QUADRUPLE THERAPY VS. NON-BISMUTH QUADRUPLE CONCOMITANT THERAPY: INTERIM ANALYSIS OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
REAL-WORLD COMPARATIVE EFFECTS OF THREE-IN-ONE SINGLE CAPSULE BISMUTH QUADRUPLE THERAPY VS. NON-BISMUTH QUADRUPLE CONCOMITANT THERAPY: INTERIM ANALYSIS OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

CLARITHROMYCIN RESISTANCE IS MORE COMMON AMONG LESS VIRULENT HELICOBACTER PYLORI STRAINS - DATA FROM AN IRISH CENTRE
CLARITHROMYCIN RESISTANCE IS MORE COMMON AMONG LESS VIRULENT HELICOBACTER PYLORI STRAINS - DATA FROM AN IRISH CENTRE

EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG): CLINICAL PHENOTYPES THROUGH MACHINE LEARNING OF FIRST-LINE TREATED PATIENTS IN SPAIN DURING THE PERIOD 2013-2018
EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG): CLINICAL PHENOTYPES THROUGH MACHINE LEARNING OF FIRST-LINE TREATED PATIENTS IN SPAIN DURING THE PERIOD 2013-2018

VONOPRAZAN-AMOXICILLIN DUAL THERAPY FOR H. PYLORI INFECTION: A SYSTEMATIC REVIEW AND META-ANALYSIS
VONOPRAZAN-AMOXICILLIN DUAL THERAPY FOR H. PYLORI INFECTION: A SYSTEMATIC REVIEW AND META-ANALYSIS

EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG): EXPERIENCE WITH SINGLE CAPSULE BISMUTH QUADRUPLE THERAPY IN 3,439 PATIENTS
EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG): EXPERIENCE WITH SINGLE CAPSULE BISMUTH QUADRUPLE THERAPY IN 3,439 PATIENTS

BISMUTH QUADRUPLE THREE-IN-ONE SINGLE CAPSULE: 3 OR 4 TIMES DAILY? SUB-ANALYSIS OF THE SPANISH DATA OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
BISMUTH QUADRUPLE THREE-IN-ONE SINGLE CAPSULE: 3 OR 4 TIMES DAILY? SUB-ANALYSIS OF THE SPANISH DATA OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG): ANALYSIS OF EMPIRICAL SECOND-LINE TREATMENTS IN EUROPE
EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG): ANALYSIS OF EMPIRICAL SECOND-LINE TREATMENTS IN EUROPE

FIRST-LINE H. PYLORI ERADICATION THERAPY IN EUROPE: RESULTS FROM 24,882 CASES OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
FIRST-LINE H. PYLORI ERADICATION THERAPY IN EUROPE: RESULTS FROM 24,882 CASES OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

PHASE 3 STUDY EVALUATING THE EFFICACY AND SAFETY OF VONOPRAZAN 20 MG VERSUS LANSOPRAZOLE 30 MG IN THE TREATMENT OF ENDOSCOPICALLY CONFIRMED DUODENAL ULCERS IN ASIAN SUBJECTS WITH OR WITHOUT HELICOBACTER PYLORI INFECTION
PHASE 3 STUDY EVALUATING THE EFFICACY AND SAFETY OF VONOPRAZAN 20 MG VERSUS LANSOPRAZOLE 30 MG IN THE TREATMENT OF ENDOSCOPICALLY CONFIRMED DUODENAL ULCERS IN ASIAN SUBJECTS WITH OR WITHOUT HELICOBACTER PYLORI INFECTION

PREVALENCE OF HELICOBACTER PYLORI DECREASED SIGNIFICANTLY DURING THE LAST 25 YEARS AMONG LITHUANIAN MEDICAL STUDENTS
PREVALENCE OF HELICOBACTER PYLORI DECREASED SIGNIFICANTLY DURING THE LAST 25 YEARS AMONG LITHUANIAN MEDICAL STUDENTS

“TEST-AND-TREAT” STRATEGY WITH UREA BREATH TEST: A COST-EFFECTIVE APPROACH FOR THE MANAGEMENT OF HELICOBACTER PYLORI-RELATED DYSPEPSIA AND THE PREVENTION OF PEPTIC ULCER IN THE UNITED KINGDOM-RESULTS OF THE HP-BREATH INITIATIVE
“TEST-AND-TREAT” STRATEGY WITH UREA BREATH TEST: A COST-EFFECTIVE APPROACH FOR THE MANAGEMENT OF HELICOBACTER PYLORI-RELATED DYSPEPSIA AND THE PREVENTION OF PEPTIC ULCER IN THE UNITED KINGDOM-RESULTS OF THE HP-BREATH INITIATIVE

PCAB-BASED HELICOBACTER PYLORI ERADICATION IN PATIENTS WITH PENICILLIN ALLERGY
PCAB-BASED HELICOBACTER PYLORI ERADICATION IN PATIENTS WITH PENICILLIN ALLERGY

RIFABUTIN TRIPLE THERAPY FOR FIRST-LINE AND RESCUE TREATMENT OF HELICOBACTER PYLORI INFECTION: A SYSTEMATIC REVIEW AND META-ANALYSIS
RIFABUTIN TRIPLE THERAPY FOR FIRST-LINE AND RESCUE TREATMENT OF HELICOBACTER PYLORI INFECTION: A SYSTEMATIC REVIEW AND META-ANALYSIS

RANDOMIZED CLINICAL TRIAL COMPARING TRIPLE THERAPY VERSUS NON-BISMUTH BASED QUADRUPLE THERAPY FOR ERADICATION OF HELICOBACTER PYLORI IN KUWAIT
RANDOMIZED CLINICAL TRIAL COMPARING TRIPLE THERAPY VERSUS NON-BISMUTH BASED QUADRUPLE THERAPY FOR ERADICATION OF HELICOBACTER PYLORI IN KUWAIT

EFFICACY AND SAFETY OF MODIFIED BISMUTH QUADRUPLE THERAPY AND CONCOMITANT THERAPY FOR HELICOBACTER PYLORI INFECTION IN RAJAVITHI HOSPITAL: A RANDOMIZED CONTROLLED TRIAL
EFFICACY AND SAFETY OF MODIFIED BISMUTH QUADRUPLE THERAPY AND CONCOMITANT THERAPY FOR HELICOBACTER PYLORI INFECTION IN RAJAVITHI HOSPITAL: A RANDOMIZED CONTROLLED TRIAL

IMPACT OF HELICOBACTER PYLORI INFECTION ON SEVERITY OF METABOLIC SYNDROME-RELATED NONALCOHOLIC FATTY LIVER DISEASE
IMPACT OF HELICOBACTER PYLORI INFECTION ON SEVERITY OF METABOLIC SYNDROME-RELATED NONALCOHOLIC FATTY LIVER DISEASE

IMPACT OF HELICOBACTER PYLORI INFECTION ON COLORECTAL CANCER AND ADENOMA FREQUENCY
IMPACT OF HELICOBACTER PYLORI INFECTION ON COLORECTAL CANCER AND ADENOMA FREQUENCY

LUMINAL NITRIC OXIDE IS INCREASED IN HELICOBACTER PYLORI-INDUCED GASTRIC INFLAMMATION AND RELATED TO VIRULENCE FACTORS OF THE BACTERIUM
LUMINAL NITRIC OXIDE IS INCREASED IN HELICOBACTER PYLORI-INDUCED GASTRIC INFLAMMATION AND RELATED TO VIRULENCE FACTORS OF THE BACTERIUM

Item 1 - 20 / 72
1
2 3 4